|
1 Indications And Usage The Kisqali ® Femara ® Co-Pack Is Indicated As Initial Endocrine-Based Therapy For The Treatment Of Pre/perimenopausal Or Postmenopausal Women With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer. Kisqali Femara Co-Pack, A Co-Packaged Product Containing Ribociclib, A Kinase Inhibitor, And Letrozole, An Aromatase Inhibitor, Is Indicated As Initial Endocrine-Based Therapy For The Treatment Of Pre/perimenopausal Or Postmenopausal Women With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer. ( 1 )
|